Insider Transactions in Q4 2024 at Regeneron Pharmaceuticals, Inc. (REGN)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 16
2024
|
Christopher R. Fenimore SVP Finance & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
491
-2.93%
|
$358,430
$730.81 P/Share
|
|
Dec 16
2024
|
Joseph J Larosa EVP General Counsel and Secret |
SELL
Payment of exercise price or tax liability
|
Direct |
702
-2.28%
|
$512,460
$730.81 P/Share
|
|
Dec 16
2024
|
Marion Mc Court EVP Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
759
-5.06%
|
$554,070
$730.81 P/Share
|
|
Dec 16
2024
|
Andrew J Murphy EVP Research |
SELL
Payment of exercise price or tax liability
|
Direct |
1,054
-2.1%
|
$769,420
$730.81 P/Share
|
|
Dec 16
2024
|
Jason Pitofsky VP Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
298
-6.01%
|
$217,540
$730.81 P/Share
|
|
Dec 16
2024
|
Neil Stahl EVP Research and Development |
SELL
Payment of exercise price or tax liability
|
Direct |
304
-0.62%
|
$221,920
$730.81 P/Share
|
|
Dec 16
2024
|
Daniel P Van Plew EVP & General Mgr, Industrial |
SELL
Payment of exercise price or tax liability
|
Direct |
969
-2.71%
|
$707,370
$730.81 P/Share
|
|
Dec 09
2024
|
Joseph J Larosa EVP General Counsel and Secret |
SELL
Payment of exercise price or tax liability
|
Direct |
492
-1.57%
|
$387,204
$787.0 P/Share
|
|
Dec 09
2024
|
Marion Mc Court EVP Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
274
-1.8%
|
$215,638
$787.0 P/Share
|
|
Dec 09
2024
|
Andrew J Murphy EVP Research |
SELL
Payment of exercise price or tax liability
|
Direct |
492
-0.97%
|
$387,204
$787.0 P/Share
|
|
Dec 09
2024
|
Daniel P Van Plew EVP & General Mgr, Industrial |
SELL
Payment of exercise price or tax liability
|
Direct |
492
-1.36%
|
$387,204
$787.0 P/Share
|
|
Dec 09
2024
|
Neil Stahl EVP Research and Development |
SELL
Payment of exercise price or tax liability
|
Direct |
466
-0.94%
|
$366,742
$787.0 P/Share
|
|
Dec 09
2024
|
Christopher R. Fenimore SVP Finance & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,140
-6.37%
|
$897,180
$787.0 P/Share
|
|
Dec 09
2024
|
Jason Pitofsky VP Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
149
-2.92%
|
$117,263
$787.0 P/Share
|
|
Dec 06
2024
|
Joseph J Larosa EVP General Counsel and Secret |
BUY
Grant, award, or other acquisition
|
Direct |
2,332
+6.94%
|
-
|
|
Dec 06
2024
|
Marion Mc Court EVP Commercial |
BUY
Grant, award, or other acquisition
|
Direct |
2,332
+13.25%
|
-
|
|
Dec 06
2024
|
Andrew J Murphy EVP Research |
BUY
Grant, award, or other acquisition
|
Direct |
3,499
+6.47%
|
-
|
|
Dec 06
2024
|
Daniel P Van Plew EVP & General Mgr, Industrial |
BUY
Grant, award, or other acquisition
|
Direct |
3,499
+8.8%
|
-
|
|
Dec 06
2024
|
Christopher R. Fenimore SVP Finance & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
2,591
+12.65%
|
-
|
|
Dec 06
2024
|
Jason Pitofsky VP Controller |
BUY
Grant, award, or other acquisition
|
Direct |
907
+15.07%
|
-
|
|
Nov 08
2024
|
Andrew J Murphy EVP Research |
SELL
Bona fide gift
|
Direct |
1,185
-2.45%
|
-
|
|
Nov 01
2024
|
Marion Mc Court EVP Commercial |
SELL
Open market or private sale
|
Direct |
1,000
-7.18%
|
$844,000
$844.61 P/Share
|
|
Nov 01
2024
|
Marion Mc Court EVP Commercial |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+6.7%
|
$381,000
$381.4 P/Share
|
|
Oct 01
2024
|
Marion Mc Court EVP Commercial |
SELL
Open market or private sale
|
Direct |
1,000
-7.18%
|
$1,054,000
$1054.06 P/Share
|
|
Oct 01
2024
|
Marion Mc Court EVP Commercial |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+6.7%
|
$381,000
$381.4 P/Share
|
|
Oct 01
2024
|
Arthur F Ryan Director |
SELL
Open market or private sale
|
Direct |
100
-0.03%
|
$104,900
$1049.73 P/Share
|